Patent Assignment
Reel/Frame 030571/0679
Security Agreement
Recorded: 2013-06-07
Received: 2013-06-07
Pages: 20
Assignor
SUPERNUS PHARMACEUTICALS, INC.
Executed: 2013-05-03
Assignee
U.S. BANK NATIONAL ASSOCIATION
CORPORATE TRUST SERVICES, ONE FEDERAL STREET, 3RD FLOOR, BOSTON, MA, 02110, UNITED STATES
Covered Properties
(51)
Methods of Producing Molindone and Its Salts
Application:
13/834,097 →
Formulations of Viloxazine
Application:
13/761,757 →
Method of Treatment of Aggression
Application:
61/727,570 →
Method of Treatment of Aggression
Application:
61/725,883 →
Formulations of Mazindol
Application:
13/638,294 →
Methods of Producing Molindone and Its Salts
Application:
61/701,007 →
Sustained-Release Formulations of Topiramate
Application:
13/595,103 →
Method of Treatment of Cns Disorders
Application:
13/512,706 →
Controlled Release Compositions of Gamma-Hydroxybutyrate
Application:
13/476,369 →
Modified Release Preparations Containing Oxcarbazepine and Derivatives Thereof
Application:
13/476,337 →
Method of Treatment of Depression
Application:
13/318,007 →
Modified Release Preparations Containing Oxcarbazepine and Derivatives Thereof
Application:
13/137,382 →
Case
Application:
29/390,208 →
Methods for Producing Viloxazine Salts and Novel Polymorphs Thereof
Application:
13/084,612 →
Stabilized Formulations of Cns Compounds
Application:
13/075,607 →
Use of a Mixture of Two or More Enteric Materials to Regulate Drug Release via Membrance or Matrix for Systemic Therapeutics
Application:
12/929,238 →
Sustained-release formulations of topiramate
Application:
12/926,936 →
Sustained-Release Formulations of Topiramate
Application:
12/926,931 →
Method of treatment of aggression
Application:
12/654,455 →
Method of treatment of attention deficit/hyperactivity disorder (ADHD)
Application:
12/585,157 →
Controlled Release Formulations of Pramipexole
Application:
12/478,979 →
Use of Isoindoles for the Treatment of Neurobehavioral Disorders
Application:
12/477,665 →
Controlled Release Formulations of Alprazolam
Application:
12/436,954 →
Method of Treating Seizures Using Modified Release Formulations of Oxcarbazepine
Application:
12/230,276 →
Modified Release Preparations Containing Oxcarbazepine and Derivatives Thereof
Application:
12/230,275 →
Enhanced immediate release formulations of topiramate
Application:
11/987,806 →
Sustained-Release Formulations of Topiramate
Application:
11/941,475 →
Topiramate Compositions and Methods of Enhancing Its Bioavailability
Application:
11/897,940 →
Enhanced Formulations of Lamotrigine
Application:
11/779,562 →
Modified-Release Preparations Containing Oxcarbazepine and Derivatives Thereof
Application:
11/734,874 →
Osmotic drug delivery system
Application:
11/412,100 →
Radiopaque Cyanoacrylate Compositions
Application:
11/328,109 →
Less Abusable Pharmaceutical Preparations
Application:
11/250,309 →
Controlled Release Compositions of Gamma-Hydroxybutyrate
Application:
11/239,638 →
Micellar systems useful for delivery of lipophilic or hydrophobic compounds
Application:
10/995,942 →
Compositions of quaternary ammonium compounds containing bioavailability enhancers
Application:
10/980,819 →
Accelerated Culture System for Intestinal Epithelial Cell Monolayers
Application:
10/797,952 →
Drug Formulation and Delivery Using Crystalline Methylated Cyclodextrins
Application:
10/770,727 →
Use of a Mixture of Two or More Enteric Materials to Regulate Drug Release via Membrane or Matrix for Systemic Therapeutics
Application:
10/751,766 →
Osmotic Delivery of Therapeutic Compounds by Solubility Enhancement
Application:
10/655,725 →
Self-Emulsifying Formulations of Fenofibrate and/or Fenofibrate Derivatives with Improved Oral Bioavailability and/or Reduced Food Effect
Application:
10/607,719 →
Fluidization of Particles for Encapsulation in Oral Dosage Pharmaceutical Products
Application:
10/437,397 →
Drug formulations having reduced abuse potential
Application:
10/435,597 →
Treatment of Oppositional Defiant Disorder and Conduct Disorder with 5-Aminoalkyl-4,5,6,7-Tetrahydro-4-Oxyindolones
Application:
10/431,491 →
Oral Capsule Formulation with Increased Physical Stability
Application:
10/324,954 →
Soluble Form Osmotic Dose Delivery System
Application:
10/324,187 →
Pharmaceutical Compositions Including Ace/Nep Inhibitors and Bioavailability Enhancers
Application:
10/134,651 →
Use of Molindone to Treat Oppositional Defiant Disorder and Conduct Disorder
Application:
10/126,065 →
Soluble Form Osmotic Dose Delivery System
Application:
10/035,077 →
Sustained Release Pharmaceutical Dosage Forms with Minimized Ph Dependent Dissolution Profiles
Application:
10/027,349 →
System for Osmotic Delivery of Pharmaceutically Active Agents
Application:
09/872,173 →